(Reuters) – Danish healthcare products maker Coloplast (CPH:COLO B) today reported a fall in full-year profit for the 1st time in 7 years after its set aside 1 billion Danish crowns ($169 million) to cover possible costs from U.S. lawsuits over its pelvic mesh products.

Pretax profit fell 12% to 3.91 billion crowns in the fiscal year ended Sept. 30, below the mean forecast of 3.16 billion crowns in a Reuters poll of analysts.

The company posted a 7% revenue increase and management expects the top line to grow 9% in the coming year.

Coloplast said it expects price pressures in 2014/15 to be in line with those of 2013/14 of almost 1%.

The 1 billion crown 1-off is the price expected to cover possible settlements and other costs relating to U.S. insurance claims on the use of mesh for treatment of pelvic organic prolapse and stress urinary incontinence.

Coloplast’s ostomy care segment grew 8%, continence care 10%, urology care 9% and wound & skin care 10%. Sales rose 6% in Europe, 10% in its other established markets and 24% in emerging markets.

"We’re particularly pleased with the sales performance in our wound & skin care business and with the 24% growth in emerging markets," CEO Lars Rasmussen said in prepared remarks.

Rival Smith & Nephew (FTSE:SN, NYSE:SNN), some of whose business areas but not all overlap with Coloplast, posted a 3% rise in 3rd-quarter trading profit, as growth in orthopedic reconstruction offset a decline in its wound management business due to a product recall.

COLO shares were 1.3% down by 12:30 GMT, underperforming the Copenhagen main index which was 0.05% higher. The company proposed a dividend payment of 7.5 crowns per share bringing to total proposed payment for the year to 11.5 crowns.

($1 = 5.9119 Danish crowns)